D3.292 - "Evaluating Inflammatory Markers in Chronic Spontaneous Urticaria: Impact of Omalizumab Treatment"

Chronic spontaneous urticaria (CSU) is defined as the occurrence of hives and/or angioedema without an identifiable trigger, persisting for six weeks or more. It is a debilitating condition that significantly impacts quality of life. Omalizumab, a monoclonal antibody targeting immunoglobulin E (IgE), has emerged as an effective treatment for CSU, offering relief when traditional antihistamines fail to control symptoms.In recent studies, inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR), eosinophil-to-lymphocyte ratio (ELR), eosinophil-to-neutrophil ratio (ENR), eosinophil-to-monocyte ratio (EMR), and platelet-to-lymphocyte ratio (PLR) have been explored for their potential use in monitoring disease activity and treatment response in CSU. These ratios provide insights into the systemic inflammatory response associated with the condition.

In an observational study, we examined 14 patients diagnosed with CSU to evaluate the changes in these inflammatory markers before and after treatment with omalizumab. Baseline ratios were established prior to the initiation of therapy. Following a one-month treatment period with omalizumab, nine patients were reassessed to determine any alterations in inflammatory markers.

Preliminary results indicate a trend towards a reduction in systemic inflammation in patients responsive to omalizumab. This reduction potentially correlates with clinical improvement in CSU symptoms. The NLR, ELR and PLR show a decreasing tendency (1,81 to 1,68, 0,104 to 0,07,113,92 to 121,81).

The ongoing research for longer period and a larger patient cohort aims to refine these biomarkers, enhancing their utility in clinical practice to tailor treatment strategies effectively for CSU patients receiving omalizumab.